Fed Chair Kevin Warsh Wants to End the Era of Easy Money. These Stocks Could Thrive in the New Market Reality.

The article argues that a Fed balance-sheet reduction under Kevin Warsh could benefit Berkshire Hathaway, JPMorgan Chase, and UnitedHealth Group. Berkshire’s $397 billion cash pile could earn more interest, JPMorgan’s $103 billion in expected interest income could rise further, and UnitedHealth could see higher investment income on its float. The piece is largely a thematic stock-picking analysis rather than a direct company event, so market impact is modest.

Analysis

The market is underestimating how QT changes the scarcity premium inside the financial system. The first-order read is “higher rates help banks and insurers,” but the second-order effect is a squeeze on levered, duration-sensitive balance sheets: smaller banks, mortgage REITs, long-duration equity multiples, and lower-quality credit are the real transmission channel. That creates a relative-value tailwind for balance-sheet fortresses with discretionary liquidity deployment, which is why the strongest expression is not simply “long financials” but long the cash-rich incumbents versus the rate-sensitive fringe.

Berkshire is the cleanest macro hedge because it monetizes QT from both sides: its cash earns more, and market dislocations improve its acquisition optionality. The underappreciated feature is convexity — every point of stress in credit or equities increases the probability Berkshire can recycle cash into distressed assets at better forward returns, while competitors are forced into defense. That makes BRK.B less a bond proxy and more a volatility monetization vehicle if QT bites harder than expected.

JPM is better framed as a market-share winner than merely a spread winner. In a QT regime, deposit betas rise unevenly and the weakest banks reprice liabilities the fastest, which tends to widen the gap between the top-tier funding franchise and everyone else. The main risk is that faster tightening initially crimps loan growth and capital markets activity, so the trade works best if the Fed move is gradual enough to pressure weaker competitors before it freezes the entire credit machine.

UNH’s setup is more nuanced: the rate benefit is real, but it is not the core driver. The stock’s appeal is that a depressed multiple plus defensive cash-generation can re-rate if rates stay elevated, yet this is lower-conviction than BRK.B or JPM because healthcare can still be hit by policy risk and reimbursement noise. Consensus is likely overemphasizing the obvious ‘higher rates help insurance’ angle and underestimating that the bigger upside is relative valuation compression if the broader market de-risks and capital rotates toward durable compounders.

Key Decisions for Investors

• Long BRK.B vs. short IWM for 3-6 months: express QT-driven liquidity withdrawal and stress in smaller caps; target outperformance if rate volatility rises and credit conditions tighten.
• Add to JPM on pullbacks over the next 1-2 months; best risk/reward if the market starts pricing a slower but sustained QT path, with upside from deposit-share gains versus regional banks.
• Initiate a pair trade long JPM / short KRE for 2-4 months: favors the balance-sheet winner over rate-sensitive regionals that face deposit pressure and mark-to-market risk.
• Buy BRK.B on market weakness rather than strength; use it as a volatility hedge with a 6-12 month horizon because optionality improves if QT triggers asset dislocations.
• Treat UNH as a lower-conviction defensive long only on valuation resets; consider call spreads rather than outright equity to cap policy/reimbursement downside while retaining multiple expansion optionality.